SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-162653
Filing Date
2024-06-17
Accepted
2024-06-17 16:37:31
Documents
13
Period of Report
2024-06-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d845947d8k.htm   iXBRL 8-K 34238
  Complete submission text file 0001193125-24-162653.txt   158150

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fulc-20240617.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20240617_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20240617_pre.xml EX-101.PRE 11263
16 EXTRACTED XBRL INSTANCE DOCUMENT d845947d8k_htm.xml XML 3634
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 241048839
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)